Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A+CHP in frontline treatment of PTCL with low CD30 expression
2020-002336-74Phase 2Active
- Sponsor
- Seagen Inc.
- Start
- Sep 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brentuximab vedotin in peripheral T-cell lymphoma (PTCL) (2 cohorts), sponsored by Seagen Inc. Primary endpoint: Objective response rate per BICR (Cheson 2007). Started Sep 2020; status: active.
02
Drugs
brentuximab vedotin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2020-002336-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002336-74.